ELI LILLY & Co
LLY · XNYSCIK 59478fmd_07PK22F2X716HNGNRT1STB4ENHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2007 to Sep 30, 2026, 75 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 18,313 | 19,974 | 21,493 | 22,320 | 24,540 | 28,318 | 28,541 | 34,124 | 45,043 | 65,179 |
| Cost of revenue | 4,161 | 4,448 | 4,682 | 4,721 | 5,483 | 7,313 | 6,630 | 7,082 | 8,418 | 11,052 |
| Gross profit | 14,152 | 15,526 | 16,812 | 17,598 | 19,057 | 21,006 | 21,912 | 27,042 | 36,624 | 54,127 |
| Realized investment gains (losses) | – | – | 27 | 403 | 1,439 | 178 | (420) | (24) | (50) | – |
| Research and development | 5,040 | 5,096 | 5,051 | 5,595 | 5,976 | 6,931 | 7,191 | 9,313 | 10,991 | 13,337 |
| Selling, general and administrative | 5,842 | 5,982 | 5,975 | 6,214 | 6,121 | 6,432 | 6,440 | 7,404 | 8,594 | 11,094 |
| Interest expense | 185 | 225 | 243 | 401 | 360 | 340 | 332 | 486 | 781 | 895 |
| Interest and investment income | 108 | 166 | 159 | 80 | 33 | 25 | 63 | 174 | 175 | – |
| Other non-operating income (expense) | 109 | 302 | 146 | 292 | 1,172 | (202) | (321) | 97 | (219) | (571) |
| Income before taxes | 3,276 | 2,305 | 3,680 | 5,266 | 7,230 | 6,156 | 6,806 | 6,554 | 12,680 | 25,731 |
| Income tax expense | 551 | 2,391 | 530 | 628 | 1,036 | 574 | 562 | 1,314 | 2,090 | 5,091 |
| Net income from continuing operations | 2,725 | (86) | 3,151 | 4,638 | 6,194 | 5,582 | 6,245 | 5,240 | 10,590 | 20,640 |
| Net income | 2,738 | (204) | 3,232 | 8,318 | 6,194 | 5,582 | 6,245 | 5,240 | 10,590 | 20,640 |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |